Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of BTDS 20 vs BTDS 5 or Oxycodone in Chronic Low Back Pain
NCT00313014Phase 3Terminated
- Sponsor
- Purdue Pharma
- Start
- Feb 2004
- Primary completion
- Sep 2005
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of v1003 in low back pain (LBP) (3 arms), sponsored by Purdue Pharma. Primary endpoint: Average Pain Over the Last 24 Hours Score at 12 weeks. Started Feb 2004; status: terminated.
02
Drugs
v1003
03
Conditions
low back pain (LBP)
Beyond the preview
Go deeper on NCT00313014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313014.